Pharmacodynamic and efficacy analysis of the BRAF inhibitor dabrafenib (GSK436) in combination with the MEK inhibitor trametinib (GSK212) in patients with BRAFV600 mutant colorectal cancer (CRC).
Ryan Bruce Corcoran
No relevant relationships to disclose
Gerald Steven Falchook
Research Funding - GlaxoSmithKline
Other Remuneration - GlaxoSmithKline
Jeffrey R. Infante
Consultant or Advisory Role - GlaxoSmithKline (U)
Omid Hamid
Research Funding - GlaxoSmithKline
Wells A. Messersmith
Consultant or Advisory Role - GlaxoSmithKline
Research Funding - GlaxoSmithKline
Adil Daud
No relevant relationships to disclose
Eunice Lee Kwak
Research Funding - GlaxoSmithKline
David P. Ryan
No relevant relationships to disclose
Razelle Kurzrock
Research Funding - GlaxoSmithKline
Chloe Evelyn Atreya
No relevant relationships to disclose
Jennifer Luan
No relevant relationships to disclose
Peng Sun
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline
Megan Schaeffer
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline
Monica Motwani
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline
Maureen R Bleam
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline
Christopher H Moy
Employment or Leadership Position - GlaxoSmithKline
Kiran Patel
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline
Keith W. Orford
Employment or Leadership Position - GlaxoSmithKline
Scott Kopetz
Consultant or Advisory Role - GlaxoSmithKline
Research Funding - GlaxoSmithKline
Alan Paul Venook
Research Funding - GlaxoSmithKline